Skip to main content
KBS_Icon_questionmark link-ico

Project launch: Remote Assessment of Disease and Relapse - Alzheimer's Disease

Remote-Assessment-Disease-and-Relapse-Alzheimers-Disease-430x275

Remote Assessment of Disease and Relapse – Alzheimer’s Disease (RADAR-AD) is now underway, applying, amongst others, the techniques and technologies developed under RADAR-CNS to assess progression of patients with early Alzheimer’s Disease.

RADAR-AD will draw on a wealth of lessons and expertise from people active in the RADAR-CNS and other projects in developing remote measuring technology to be used by patients with early Alzheimer’s.

Like RADAR-CNS, which looks at diagnoses linked to the central nervous system, RADAR-AD is a Public Private Partnership funded by the Innovative Medicines Initiative, with representation from academic institutions, small-to-medium enterprises, public organisations and pharmaceutical companies. Professor Dag Aarsland, Chair of Old Age Psychiatry at the IoPPN is leading the project together with Vaibhav Narayan from Janssen Pharmaceutica. 

The team will seek solutions that take account of particular characteristics shared by many people with Alzheimer’s: many are older and may not have had much exposure to technology, and their condition may also make it more difficult for them to learn to handle technical devices. A key aim of the project is to find ways to measure any reduction in ability to live and function independently early on in the course of an individual’s condition.

Professor Aarsland commented: ‘There is more and more interest in the use of widely available and affordable digital technology to improve outcomes for people with Alzheimer’s. Our hope is that RADAR-AD will result in clinical and technological advancements so that valuable new treatments can be identified and implemented. People with Alzheimer’s Disease will be fundamentally involved in the design and development of the project so that the solutions we generate are acceptable and appropriate for people in their everyday lives.’

Contact

For further media information please contact: Amy Edmunds, Communications and Engagement Manager, NIHR Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, amy.edmunds@kcl.ac.uk / 020 7848 0495 or 07500 224 906